Zai Lab

ZLAB · HONG

$24.03+$1.99 (+9.03%)TodayMarket closed · Oct 23, 7:39 PM ET

Prev close $22.04

Latest news

Press releaseOct 23, 6:33 AM ETBusiness Wire
Zai Lab’s Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer
Press releaseOct 22, 8:52 PM ETBusiness Wire
Zai Lab Announces $250 Million Private Placement
Press releaseOct 21, 7:30 AM ETBusiness Wire
Zai Lab to Announce Third Quarter 2026 Financial Results and Recent Corporate Updates on November 5, 2026
Press releaseOct 14, 7:00 AM ETBusiness Wire
Zai Lab to Present Data From First Clinical Trial Evaluating ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, for Atopic Diseases
NewsOct 5, 8:34 AM ET
Zai Lab Reports Q2 2026 Results: Full Earnings Call Transcript
Press releaseSep 29, 7:00 AM ETBusiness Wire
Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
NewsSep 28, 8:46 AM ETGianni di Poce
The Insider Report: The Leaders Have Taken Off
NewsSep 10, 8:02 AM ETAvi Kapoor
Limoneira Posts Downbeat Q3 Results, Joins Cooper Companies, Navan And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
NewsSep 2, 10:26 AM ETAvi Kapoor
Sirius XM, Dell, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday
Press releaseAug 17, 6:00 AM ETBusiness Wire
Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
Press releaseAug 6, 6:30 AM ETBusiness Wire
Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates
Press releaseAug 3, 7:00 AM ETBusiness Wire
U.S. FDA Grants Orphan Drug Designation to Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)
Press releaseJul 22, 7:30 AM ETBusiness Wire
Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026
Press releaseJun 16, 7:00 AM ETBusiness Wire
Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas
Press releaseJun 8, 8:34 PM ETBusiness Wire
Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer
Press releaseMay 21, 6:09 PM ETBusiness Wire
Zai Lab Announces Changes to Senior Leadership Team
NewsMay 18, 8:02 AM ETAvi Kapoor
UnitedHealth, Regeneron Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Press releaseMay 11, 7:00 AM ETBusiness Wire
Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)
Press releaseMay 7, 6:00 AM ETBusiness Wire
Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates
Press releaseApr 22, 7:30 AM ETBusiness Wire
Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026
Press releaseApr 18, 9:00 AM ETBusiness Wire
Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic Diseases
Press releaseApr 17, 3:01 PM ETBusiness Wire
Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas
Press releaseApr 1, 7:30 AM ETBusiness Wire
Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy
Press releaseMar 17, 4:35 PM ETBusiness Wire
Zai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC)
NewsFeb 26, 9:10 AM ET
Zai Lab: Q4 Earnings Insights
NewsFeb 26, 7:10 AM ET
Zai Lab Q4 Earnings Summary & Key Takeaways
Press releaseFeb 26, 7:00 AM ETBusiness Wire
Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
NewsFeb 25, 12:03 PM ET
An Overview of Zai Lab's Earnings
Press releaseFeb 10, 8:30 AM ETBusiness Wire
Zai Lab to Announce Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates on February 26, 2026
Press releaseFeb 5, 9:35 AM ETPRNewswire
$207B Market Shift: The Race for Fast Track Approval in Oncology
Press releaseJan 13, 8:00 AM ETBusiness Wire
Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference
Press releaseJan 6, 7:30 AM ETBusiness Wire
Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO™ (repotrectinib) for Patients with NTRK-Positive Solid Tumors
Press releaseJan 5, 7:30 AM ETBusiness Wire
Zai Lab to Present at 44th Annual J.P. Morgan Healthcare Conference
NewsNov 6, 6:12 AM ET
Earnings Scheduled For November 6, 2025
NewsSep 11, 8:02 AM ETBamboo Works
Zai Lab's Double Whammy: Earnings Miss, Phase 3 Setback
NewsSep 4, 2:35 PM ETVandana Singh
Amgen Faces Setback As Final Data Weakens Case For Gastric Cancer Drug
NewsSep 4, 8:17 AM ETAvi Kapoor
C3.ai Posts Downbeat Results, Joins GitLab, Salesforce And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Zai Lab’s Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer

Zai Lab Announces $250 Million Private Placement

Zai Lab to Announce Third Quarter 2026 Financial Results and Recent Corporate Updates on November 5, 2026

Zai Lab to Present Data From First Clinical Trial Evaluating ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, for Atopic Diseases

Zai Lab Reports Q2 2026 Results: Full Earnings Call Transcript

Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

The Insider Report: The Leaders Have Taken Off

Limoneira Posts Downbeat Q3 Results, Joins Cooper Companies, Navan And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session

Sirius XM, Dell, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday

Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates

U.S. FDA Grants Orphan Drug Designation to Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)

Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026

Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas

Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer

Zai Lab Announces Changes to Senior Leadership Team

UnitedHealth, Regeneron Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)

Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates

Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026

Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic Diseases

Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas

Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy

Zai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC)

Zai Lab: Q4 Earnings Insights

Zai Lab Q4 Earnings Summary & Key Takeaways

Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates

An Overview of Zai Lab's Earnings

Zai Lab to Announce Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates on February 26, 2026

$207B Market Shift: The Race for Fast Track Approval in Oncology

Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference

Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO™ (repotrectinib) for Patients with NTRK-Positive Solid Tumors

Zai Lab to Present at 44th Annual J.P. Morgan Healthcare Conference

Earnings Scheduled For November 6, 2025

Zai Lab's Double Whammy: Earnings Miss, Phase 3 Setback

Amgen Faces Setback As Final Data Weakens Case For Gastric Cancer Drug

C3.ai Posts Downbeat Results, Joins GitLab, Salesforce And Other Big Stocks Moving Lower In Thursday's Pre-Market Session